Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.
To learn more about each of our products, simply click on a product below:
Myriad myRisk Hereditary Cancer is a 25-gene panel for the identification of clinically significant mutations impacting inherited risks for eight important cancers. Blending genetic test status AND personal/family cancer history into clinically significant risk assessment and follow-up, the myRisk Hereditary Cancer test represents the next generation of cancer genetic testing.
Hereditary Breast and Ovarian Cancer
BRACAnalysis® testing assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.
Hereditary Colorectal Cancer
COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes.
COLARIS AP testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.
ProlarisTM is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness. The Prolaris result provides 10-year risks for prostate cancer specific mortality in the biopsy setting or biochemical recurrence in the post-prostatectomy setting.
Prognostic gene expression panels in cancer: Breast Cancer
EndoPredict® is a multi-gene test for breast cancer patients.
EndoPredict® is a second generation gene expression analysis used to determine the risk of metastasis with endocrine therapy alone in patients with ER-positive HER2-negative primary breast cancer. Stratifying patients into clear High and Low Risk categories, EndoPredict reliably predicts early and late metastases.
A companion diagnostic tumor test for ovarian cancer patients, to determine who may benefit from PARP inhibitor therapy.
Tumor BRACAnalysis CDx is a CE marked companion diagnostic tumor test for ovarian cancer patients. This test can detect up to 50% more patients with mutations in the BRCA1 and BRCA2 genes. BRCA mutation analysis is essential in ovarian cancer patients to identify the subset of women who are most likely to benefit from PARP inhibitors.
BRACAnalysis is a companion diagnostic blood test for ovarian cancer patients, to detect germline mutations in the BRCA1 and BRCA2 genes. BRCA mutation analysis is essential in ovarian cancer patients to identify the subset of women who are most likely to benefit from PARP inhibitors.